Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.
Serrano D, Cella D, Husereau D, King-Kallimanis B, Mendoza T, Salmonson T, Stone A, Zaleta A, Dhanda D, Moshyk A, Liu F, Shields AL, Taylor F, Spite S, Shaw JW, Braverman J. Serrano D, et al. Among authors: dhanda d. Qual Life Res. 2024 Apr;33(4):1075-1084. doi: 10.1007/s11136-023-03587-8. Epub 2024 Jan 24. Qual Life Res. 2024. PMID: 38265747 Free PMC article.
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J. Rivolo S, et al. Among authors: dhanda d. PLoS One. 2021 Nov 12;16(11):e0259251. doi: 10.1371/journal.pone.0259251. eCollection 2021. PLoS One. 2021. PMID: 34767564 Free PMC article.
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Tanaka E, et al. Among authors: dhanda d. PLoS One. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566. eCollection 2022. PLoS One. 2022. PMID: 36383610 Free PMC article.
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Delforge M, et al. Among authors: dhanda ds. Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3. Leuk Res. 2023. PMID: 37087950 Free article. Clinical Trial.
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies FE, Delforge M, Weisel K, Marshall TS, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D. Rodríguez Otero P, et al. Among authors: dhanda d. Leuk Lymphoma. 2023 Nov-Dec;64(11):1864-1869. doi: 10.1080/10428194.2023.2235042. Epub 2023 Jul 27. Leuk Lymphoma. 2023. PMID: 37497883 No abstract available.
30 results